Hologic (HOLX) Receives Coverage Optimism Rating of 0.16
Media coverage about Hologic (NASDAQ:HOLX) has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Hologic earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 46.0429998179631 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Hologic (HOLX) Lowered to Hold at Deutsche Bank (americanbankingnews.com)
- Deutsche Bank Downgrades Hologic, Says Core Businesses Face Structural Challenges (msn.com)
- Hologic Preliminary Revenues Increase 8pc to Approximately USD 791 Million in the First Quarter of Fiscal 2018 (newkerala.com)
- Hologic, Inc. — Moody’s assigns Ba3 rating to Hologic’s senior unsecured bonds (finance.yahoo.com)
- Hologic Announces Pricing of Offering of $1 Billion of Senior Notes (prnewswire.com)
Several research firms have recently issued reports on HOLX. Deutsche Bank lowered Hologic from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a report on Friday. BidaskClub lowered Hologic from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. Evercore ISI began coverage on Hologic in a report on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and set a $50.00 target price (up from $48.00) on shares of Hologic in a report on Tuesday, January 9th. Finally, Bank of America raised Hologic from a “neutral” rating to a “buy” rating and set a $50.00 target price on the stock in a report on Thursday, January 4th. One research analyst has rated the stock with a sell rating, four have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $48.79.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The business had revenue of $802.90 million during the quarter, compared to the consensus estimate of $792.54 million. During the same period in the prior year, the company earned $0.52 EPS. Hologic’s revenue for the quarter was up 10.5% on a year-over-year basis. analysts anticipate that Hologic will post 2.16 EPS for the current year.
In related news, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $39.84, for a total transaction of $40,756.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Elaine Ullian sold 9,282 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $40.50, for a total value of $375,921.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,099 shares of company stock valued at $487,223. 0.79% of the stock is owned by corporate insiders.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.